Skip to main content
Download PDF
Download ePub

Correction: Secondary outcomes and qualitative findings of an open-label feasibility trial of lisdexamfetamine dimesylate for adults with bulimia nervosa

Journal of Eating Disorders volume 11, Article number: 205 (2023) Cite this article

The Original Article was published on 22 May 2023

Correction:Journal of Eating Disorders (2023) 11:81 https://doi.org/10.1186/s40337-023-00796-x 

The original article [1] has incomplete funding information. The sponsorship from Takeda Pharmaceutical Australia to cover the Article Processing Charge was not mentioned in the Funding note. The correct Funding note is as follows:

Funding

This work was supported by the Nova Scotia Health Authority Research Fund and the Dalhousie Department of Psychiatry (Award No. 1023016). The Nova Scotia Health Authority Research Fund and the Dalhousie Department of Psychiatry were not involved in the design of the study, data collection, analysis and interpretation, or in writing the manuscript. The article has received sponsorship from Takeda Pharmaceutical Australia to cover the Article Processing Charge.

The original article [1] has been corrected.

References

  1. Dixon L, Bartel S, Brown V, et al. Secondary outcomes and qualitative findings of an open-label feasibility trial of lisdexamfetamine dimesylate for adults with bulimia nervosa. J Eat Disord. 2023;11:81. https://doi.org/10.1186/s40337-023-00796-x.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

  1. Laura Dixon and Sara Bartel should be considered joint first author.

  2. Aaron R. Keshen and Abraham Nunes should be considered joint senior author.

Authors and Affiliations

  1. Eating Disorder Program, Nova Scotia Health Authority, Halifax, NS, Canada

    Laura Dixon, Sara Bartel, Victoria Brown, Sarrah I. Ali, Susan Gamberg & Aaron R. Keshen

  2. Department of Psychiatry, Dalhousie University, Halifax, NS, Canada

    Susan Gamberg, Andrea Murphy, Abraham Nunes & Aaron R. Keshen

  3. College of Pharmacy, Dalhousie University, Halifax, NS, Canada

    Andrea Murphy

  4. College of Doctoral Studies, University of Phoenix, Tempe, AZ, USA

    Katherine L. Brewer

  5. Lindner Center of HOPE, Mason, OH, USA

    Susan L. McElroy

  6. Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA

    Susan L. McElroy

  7. Department of Psychiatry, Centre for Addiction and Mental Health, Institute of Medical Science, University of Toronto, Toronto, ON, Canada

    Allan Kaplan

  8. Faculty of Computer Science, Dalhousie University, Halifax, NS, Canada

    Abraham Nunes

Authors
  1. Laura Dixon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sara Bartel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Victoria Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sarrah I. Ali
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Susan Gamberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Andrea Murphy
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Katherine L. Brewer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Susan L. McElroy
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Allan Kaplan
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Abraham Nunes
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Aaron R. Keshen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aaron R. Keshen.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at https://doi.org/10.1186/s40337-023-00796-x.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dixon, L., Bartel, S., Brown, V. et al. Correction: Secondary outcomes and qualitative findings of an open-label feasibility trial of lisdexamfetamine dimesylate for adults with bulimia nervosa. J Eat Disord 11, 205 (2023). https://doi.org/10.1186/s40337-023-00926-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s40337-023-00926-5

Journal of Eating Disorders

ISSN: 2050-2974